The US Food and Drug Administration (FDA) has granted an Emergency Use Authorization (EUA) to Roche’s intravenous Actemra (tocilizumab) to treat hospitalised adults and paediatric patients aged two years or above with Covid-19.

The treatment is indicated for individuals who are on systemic corticosteroids and need additional oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A humanised monoclonal antibody, Actemra hinders the interleukin-6 receptor to lower inflammation.

The FDA granted EUA based on data from four trials that analysed the safety and efficacy of Actemra in more than 5,500 Covid-19 patients in the hospital.

Researchers in the UK led the RECOVERY Actemra study that enrolled more than 4,000 subjects. The international, placebo-controlled EMPACTA, COVACTA and REMDACTA trials were funded by Roche.

According to the results from these randomised trials, the drug demonstrated the ability to lower the risk of mortality over 28 days of follow-up and reduced hospitalisation time.

Furthermore, a decline in the risk of subjects requiring ventilation or death through the follow-up period was observed.

Constipation, anxiety, diarrhoea, insomnia, hypertension and nausea were the most commonly noted adverse reactions while no new safety signals linked to Actemra were observed in these studies.

In April last year, early data from a clinical trial in France demonstrated an encouraging profile of Actemra to treat seriously ill Covid-19 patients.

Roche Global Product Development head and chief medical officer Levi Garraway said: “Even with the availability of vaccines and declines in deaths from Covid-19 in various parts of the world, we continue to see new hospitalisations from severe forms of the disease.

“We are pleased that Actemra is now authorised as an option that may help improve outcomes for adults and children hospitalised with Covid-19 in the United States.”

Currently, Actemra is approved for treating adults with moderate to severe rheumatoid arthritis who have received one or more disease-modifying antirheumatic drugs.

Subcutaneous Actemra is approved for various other indications including giant cell arteritis, active polyarticular juvenile idiopathic arthritis and for reducing pulmonary function decline rate in adults with systemic sclerosis-associated interstitial lung disease.